Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the injectable drugs. In the 72-week trial - led by an investigator at Weill Cornell Medicine and NewYork-Presbyterian and conducted with the University of Texas McGovern Medical School, the David Geffen School of Medicine at the University of California, Los Angeles, the University College Dublin and Eli Lilly

A phenomenon largely ignored since its discovery 100 years ago appears to be a crucial component of diabetic pain, according to new research from The University of Texas at Dallas' Center for Advanced Pain Studies (CAPS).

Findings from a new study, published in Nature Communications, suggest that cell clusters called Nageotte nodules are a strong indicator of nerve cell death in human sensory ganglia.

The Food and Drug Administration's approval in 2023 of lecanemab - a novel Alzheimer's therapy shown in clinical trials to modestly slow disease progression - was met with enthusiasm by many in the field as it represented the first medication of its kind able to influence the disease. But side effects - brain swelling and bleeding - emerged during clinical trials that have left some patients and physicians hesitant about the treatment.

A new publication shines a spotlight on HER3, a long-overlooked member of the ErbB receptor family, revealing its critical role in cancer progression and resistance to therapy. Once considered a passive player due to its weak kinase activity, HER3 is now recognized as a major contributor to the survival and spread of various solid tumors, including breast, lung, colorectal, pancreatic, and gynecologic cancers.

Mitochondrial DNA (mtDNA) editing has emerged as a revolutionary approach in the fight against neurodegenerative diseases (NDDs). As these diseases continue to impose a significant global health burden, the innovative use of mitochondrial gene editing offers a promising avenue to address their underlying causes. The dysfunction of mitochondria, triggered by mutations in mtDNA, is now recognized as a pivotal factor contributing to the development of several debilitating conditions,

An international team of scientists led by the Medical University of Vienna has identified similarities in the mechanisms of diabetes and cancer: as the researchers show, the protein PPARγ, which is central to the regulation of metabolic processes, can also influence the growth of prostate cancer cells. PPARγ is already known to be a target of certain drugs used to treat type 2 diabetes.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it will invest USD 50 billion into the United States of America in the next five years. These investments further strengthen Roche's already significant US footprint with 13 manufacturing and 15 R&D sites across the Pharmaceutical and Diagnostics Divisions, and are expected to create more than 12,000 new jobs, including nearly 6,500 construction jobs, as well as 1,000 jobs at new and expanded facilities.

Groundbreaking research from the University of Virginia School of Medicine has revealed crucial new insights into the immune systems of COVID-19 survivors, particularly those struggling with persistent breathing issues. The study shows that these patients have distinct changes in their immune system that link to the severity of their lung damage. This discovery holds promise for developing targeted treatments for the lung complications of Long COVID.

The mitochondrion, often referred to as the powerhouse of the cell, plays critical roles in cellular function, making it a prime organelle to target for fundamental studies, metabolic engineering, and disease therapies. With only a limited number of existing mitochondrial targeting sequences, a new study from the Carl R. Woese Institute for Genomic Biology demonstrates the utility of generative artificial intelligence for designing new ones.

People who are given a vaccine for shingles have a 23% lower risk of cardiovascular events, including stroke, heart failure, and coronary heart disease, according to a study of more than a million people published in the European Heart Journal.

The protective effect of the vaccine lasts for up to eight years and is particularly pronounced for men, people under the age of 60 and those with unhealthy lifestyles, such as smoking, drinking alcohol and being inactive.

Researchers at Karolinska Institutet in Sweden have developed a technique that enables efficient delivery of therapeutic proteins and RNA to cells. The method, presented in Nature Communications, shows promising results in animal studies to deliver gene editors and protein therapeutics.

The method is based on so-called extracellular vesicles (EVs), tiny bubbles that are naturally secreted by cells and can transport biologically active molecules between cells.

A Ludwig Cancer Research study has identified a specific mode of fat uptake by immune cells within tumors that serves as a metabolic checkpoint against anti-cancer immune responses. Harnessing that insight, researchers led by Ludwig Lausanne's Ping-Chih Ho and Yi-Ru Yu - along with Sheue-Fen Tzeng and Chin-Hsien Tsai, former post-docs in the Ho lab who now lead their own labs at Taipei Medical University in Taiwan - have developed a humanized antibody to dismantle that barrier as a potential cancer immunotherapy.

Novartis today announced that it has entered into an agreement to acquire Regulus Therapeutics, a San Diego-based, publicly traded (Nasdaq: RGLS) clinical-stage biopharmaceutical company focused on developing microRNA therapeutics. Regulus' lead asset, farabursen, is a potential first-in-class, next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD).

University of Oregon (UO) researchers have uncovered a molecule produced by yeast living on human skin that showed potent antimicrobial properties against a pathogen responsible for a half-million hospitalizations annually in the United States.

It's a unique approach to tackling the growing problem of antibiotic-resistant bacteria.

Hepatocellular carcinoma (HCC), the most common form of liver cancer, continues to pose a significant global health challenge due to its high mortality rate and limited treatment options. However, a new frontier in cancer therapy has emerged, focusing on neddylation modification, a crucial cellular process that influences cancer progression. The latest insights into this mechanism provide hope for targeted therapies that could revolutionize the treatment landscape for HCC.

Chemists have confirmed a 67-year-old theory about vitamin B1 by stabilizing a reactive molecule in water - a feat long thought impossible. The discovery not only solves a biochemical mystery, but also opens the door to greener, more efficient ways of making pharmaceuticals.

The molecule in question is a carbene, a type of carbon atom with only six valence electrons. Generally, carbon is stable with eight electrons around it. With only six electrons, it is chemically unstable and highly reactive.

Antibodies are best known for their ability to latch onto and neutralize bacteria, viruses and other pathogens. But these immune proteins can do more than that: They also activate other components of the immune system, which then go to work to clear an infection. A new study from Scripps Research explores the factors that influence how effectively antibodies engage specific immune cells.

Their results, described April 22, 2025 in Cell Reports, indicate that a higher ratio of antibodies to viral protein - in this case, a part of HIV - better engages two specific types of immune cells.

BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned subsidiary of Bayer AG, announced the publication of the 18-month data from its Phase 1 exPDite clinical trial for bemdaneprocel in the journal Nature.

"The concept of "rebuilding" brain networks that have been lost to disease is compelling," said Claire Henchcliffe, MD, chair of the UC Irvine School of Medicine's Department of Neurology at the University of California, Irvine and one of the study's Principal Investigators,

When the immune system does not function properly, individuals become more susceptible to infections caused by viruses, bacteria, or fungi. Researchers from Radboud university medical center have demonstrated that an existing drug can revive immune cells that are not functioning correctly. These findings provide leads for further research in patients admitted to the intensive care unit (ICU) with sepsis.

A common pinworm medication may stop and reverse cancer growth in Merkel cell carcinoma, an aggressive form of skin cancer, according to research led by University of Arizona Cancer Center researchers and published in the Journal of Clinical Investigation.

Merkel cell carcinoma is a rare but fast-growing neuroendocrine cancer that is three to five times more likely than melanoma to be deadly.